Cytokine control of megakaryopoiesis

Growth Factors

Volumn 36, Issue 3-4, 2018, Pages 89-103

  Behrens, Kira ^a,b   Alexander, Warren S ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cytokine; Megakaryopoiesis; Mpl receptor; platelet; thrombopoietin

Indexed keywords

ALPHA INTERFERON; ANGIOPOIETIN RELATED PROTEIN 4; CELL SURFACE RECEPTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR 4; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 21; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 9; LEUKEMIA INHIBITORY FACTOR; MPL PROTEIN; SPHINGOSINE 1 PHOSPHATE; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; THROMBOPOIETIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C;

CELL MIGRATION; HUMAN; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STEADY STATE; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPOIESIS; ANIMAL; CYTOLOGY; GENETICS; HEMATOPOIESIS; MEGAKARYOBLAST; METABOLISM; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; CYTOKINES; HEMATOPOIESIS; HUMANS; MEGAKARYOCYTE PROGENITOR CELLS; MEGAKARYOCYTES;

EID: 85055042657     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977194.2018.1498487     Document Type: Review

References (153)

1. Adolfsson J, Månsson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, Bryder D, et al. 2005. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 121:295–306.
2. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. 1996. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87:2162–2170.
3. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, et al. 2016. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 127:1307–1316.
4. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, et al. 1999. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94:3694–3701.
5. Aschoff L. 1893. Ueber capilläre Embolie von riesenkernhaltigen Zellen. Archiv Für Pathologische Anatomie Und Physiologie Und Für Klinische Medicin 134:11–25.
6. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, et al. 2004. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10:64–71.
7. Avraham H, Vannier E, Cowley S, Jiang SX, Chi S, Dinarello CA, Zsebo KM, Groopman JE. 1992. Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood 79:365–371.
8. Ballmaier M, Germeshausen M, Krukemeier S, Welte K. 2003. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci 996:17–25.
9. Bellanné-Chantelot C, Mosca M, Marty C, Favier R, Vainchenker W, Plo I. 2017. Identification of MPL R102P Mutation in Hereditary Thrombocytosis. Front Endocrinol (Lausanne) 8:235
10. Benbarche S, Strassel C, Angénieux C, Mallo L, Freund M, Gachet C, Lanza F, la Salle de H. 2017. Dual role of IL-21 in megakaryopoiesis and platelet homeostasis. Haematologica 102:637–646.
11. Bernad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC. 1994. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity 1:725–731.
12. Bersenev A, Wu C, Balcerek J, Tong W. 2008. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 118:2832–2844.
13. Bikfalvi A, Han ZC, Fuhrmann G. 1992. Interaction of fibroblast growth factor (FGF) with megakaryocytopoiesis and demonstration of FGF receptor expression in megakaryocytes and megakaryocytic-like cells. Blood 80:1905–1913.
14. Bluteau D, Lordier L, Di Stefano A, Chang Y, Raslova H, Debili N, Vainchenker W. 2009. Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 7 Suppl 1:227–234.
15. Broudy VC, Lin NL, Kaushansky K. 1995. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719–1726.
16. Broudy VC, Lin NL. 2004. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25:52–60.
17. Burstein SA, Mei RL, Henthorn J, Friese P, Turner K. 1992. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 153:305–312.
18. Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. 2014. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 123:3887–3894.
19. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, et al. 2006. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355:1672–1681.
20. Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, et al. 2003. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 101:1316–1323.
21. Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R-I, Marty C, Gryshkova V, et al. 2016. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 127:1325–1335.
22. Chang MS, McNinch J, Basu R, Shutter J, Hsu RY, Perkins C, Mar V, et al. 1995. Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene. J Biol Chem 270:511–514.
23. Chen Q, Solar G, Eaton DL, de Sauvage FJ. 1998. IL-3 does not contribute to platelet production in c-Mpl-deficient mice. Stem Cells 16 Suppl 2:31–36.
24. Coppola S, Narciso L, Feccia T, Bonci D, Calabrò L, Morsilli O, Gabbianelli M, et al. 2006. Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. Cell Death Differ 13:61–74.
25. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, et al. 1997. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276:1696–1699.
26. Dasouki M, Roberts J, Santiago A, Saadi I, Hovanes K. 2014. Confirmation and further delineation of the 3q26.33-3q27.2 microdeletion syndrome. Eur J Med Genet 57:76–80.
27. Dasouki MJ, Rafi SK, Olm-Shipman AJ, Wilson NR, Abhyankar S, Ganter B, Furness LM, et al. 2013. Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. Blood 122:3440–3449.
28. de Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, Moore MW. 1996. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J. Exp. Med 183:651–656.
29. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, et al. 1994. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533–538.
30. Decker M, Leslie J, Liu Q, Ding L. 2018. Hepatic thrombopoietin is required for bone marrow hematopoietic stem cell maintenance. Science 360:106–110.
31. Defour J-P, Itaya M, Gryshkova V, Brett IC, Pecquet C, Sato T, Smith SO, Constantinescu SN. 2013. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proceedings of the National Academy of Sciences 110:2540–2545.
32. Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, et al. 2014. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123:1818–1825.
33. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, et al. 2004. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:4198–4200.
34. Drayer AL, Boer A-K, Los EL, Esselink MT, Vellenga E. 2005. Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase. Stem Cells 23:240–251.
35. El-Harith E-HA, Roesl C, Ballmaier M, Germeshausen M, Frye-Boukhriss H, Neuhoff von N, Becker C, et al. 2009. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol 144:185–194.
36. Erickson-Miller CL, Delorme E, Tian S-S, Hopson CB, Stark K, Giampa L, Valoret EI, et al. 2005. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 33:85–93.
37. Escary JL, Perreau J, Duménil D, Ezine S, Brûlet P. 1993. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 363:361–364.
38. Feese MD, Tamada T, Kato Y, Maeda Y, Hirose M, Matsukura Y, Shigematsu H, et al. 2004. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA 101:1816–1821.
39. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ. 1996. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87:2154–2161.
40. Fuentes R, Wang Y, Hirsch J, Wang C, Rauova L, Worthen GS, Kowalska MA, Poncz M. 2010. Infusion of mature megakaryocytes into mice yields functional platelets. J Clin Invest 120:3917–3922.
41. Fujiki H, Kimura T, Minamiguchi H, Harada S, Wang J, Nakao M, Yokota S, et al. 2002. Role of human interleukin-9 as a megakaryocyte potentiator in culture. Exp Hematol 30:1373–1380.
42. Gainsford T, Nandurkar H, Metcalf D, Robb L, Begley CG, Alexander WS. 2000. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 95:528–534.
43. Gandhi MJ, Pendergrass TW, Cummings CC, Ihara K, Blau CA, Drachman JG. 2005. Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation. Exp Hematol 33:1215–1221.
44. Geddis AE, Fox NE, Tkachenko E, Kaushansky K. 2007. Endomitotic megakaryocytes that form a bipolar spindle exhibit cleavage furrow ingression followed by furrow regression. Cell Cycle 6:455–460.
45. Germeshausen M, Ballmaier M, Welte K. 2006. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat 27:296
46. Gordon MS, Hoffman R. 1992. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood 80:302–307.
47. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, Hoffman R, et al. 1996. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615–3624.
48. Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, Hoffmeister KM. 2015. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 21:47–54.
49. Gruber TA, Downing JR. 2015. The biology of pediatric acute megakaryoblastic leukemia. Blood 126:943–949.
50. Haas S, Hansson J, Klimmeck D, Loeffler D, Velten L, Uckelmann H, Wurzer S, et al. 2015. Inflammation-Induced Emergency Megakaryopoiesis Driven by Hematopoietic Stem Cell-like Megakaryocyte Progenitors. Cell Stem Cell 17:422–434.
51. Harker LA, Marzec UM, Kelly AB, Cheung E, Tomer A, Nichol JL, Hanson SR, Stead RB. 1997. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 89:155–165.
52. Hitchcock IS, Chen MM, King JR, Kaushansky K. 2008. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 112:2222–2231.
53. Hitchcock IS, Kaushansky K. 2014. Thrombopoietin from beginning to end. Br J Haematol 165:259–268.
54. Hoffman R. 1989. Regulation of megakaryocytopoiesis. Blood 74:1196–1212.
55. Hong W-J, Gotlib J. 2014. Hereditary erythrocytosis, thrombocytosis and neutrophilia. Best Pract Res Clin Haematol 27:95–106.
56. Howell WH, Donahue DD. 1937. THE PRODUCTION OF BLOOD PLATELETS IN THE LUNGS. J. Exp. Med 65:177–203.
57. Huang H, Cantor AB. 2009. Common features of megakaryocytes and hematopoietic stem cells: what's the connection? J Cell Biochem 107:857–864.
58. Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T. 1999. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 96:3132–3136.
59. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Maruyama Y. 1990. Effect of recombinant granulocyte-macrophage colony-stimulating factor on murine thrombocytopoiesis in vitro and in vivo. Blood 75:1433–1438.
60. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA. 1989. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 86:5953–5957.
61. Italiano JE, Lecine P, Shivdasani RA, Hartwig JH. 1999. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 147:1299–1312.
62. Iwasaki H, Akashi K. 2007. Hematopoietic developmental pathways: on cellular basis. Oncogene 26:6687–6696.
63. Jenkins BJ, Quilici C, Roberts AW, Grail D, Dunn AR, Ernst M. 2002. Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. Exp Hematol 30:1248–1256.
64. Jenkins BJ, Roberts AW, Najdovska M, Grail D, Ernst M. 2005. The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 105:3512–3520.
65. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL. 2007. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109:4739–4741.
66. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, et al. 2007. Dynamic visualization of thrombopoiesis within bone marrow. Science 317:1767–1770.
67. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, et al. 2001. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98:2720–2725.
68. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. 1995. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55:5687–5692.
69. Kaushansky K. 2009. Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program 2009:147–152.
70. Kim ES. 2016. Lusutrombopag: First Global Approval. Drugs 76:155–158.
71. Kim M-J, Park SH, Opella SJ, Marsilje TH, Michellys P-Y, Seidel HM, Tian S-S. 2007. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem 282:14253–14261.
72. Kimura S, Roberts AW, Metcalf D, Alexander WS. 1998. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 95:1195–1200.
73. King S, Germeshausen M, Strauss G, Welte K, Ballmaier M. 2005. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 131:636–644.
74. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, et al. 2013. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390.
75. Kosaki G. 2005. In vivo platelet production from mature megakaryocytes: does platelet release occur via proplatelets?. Int J Hematol 81:208–219.
76. Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, Sheridan W, McCullough J. 2001. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98:1339–1345.
77. Kuter DJ. 2007. New thrombopoietic growth factors. Blood 109:4607–4616.
78. Kuter DJ. 2013. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 98:10–23.
79. Lane WJ, Dias S, Hattori K, Heissig B, Choy M, Rabbany SY, Wood J, et al. 2000. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 96:4152–4159.
80. Lannutti BJ, Drachman JG. 2004. Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors. Blood 103:3736–3743.
81. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, et al. 2017. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 544:105–109.
82. Levin J, Cocault L, Demerens C, Challier C, Pauchard M, Caen J, Souyri M. 2001. Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response. Blood 98:1019–1027.
83. Levine RF, Eldor A, Shoff PK, Kirwin S, Tenza D, Cramer EM. 1993. Circulating megakaryocytes: delivery of large numbers of intact, mature megakaryocytes to the lungs. Eur J Haematol 51:233–246.
84. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248.
85. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, et al. 1994. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565–568.
86. Lorenz V, Ramsey H, Liu Z-J, Italiano J, Hoffmeister K, Bihorel S, Mager D, et al. 2017. Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice. Thromb Haemost 117:2322–2333.
87. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H. 2005. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102:18962–18967.
88. Mach N, Lantz CS, Galli SJ, Reznikoff G, Mihm M, Small C, Granstein R, et al. 1998. Involvement of interleukin-3 in delayed-type hypersensitivity. Blood 91:778–783.
89. Mandrile G, Dubois A, Hoffman JD, Uliana V, Di Maria E, Malacarne M, Coviello D, et al. 2013. 3q26.33-3q27.2 microdeletion: a new microdeletion syndrome? Eur J Med Genet 56:216–221.
90. Månsson R, Hultquist A, Luc S, Yang L, Anderson K, Kharazi S, Al-Hashmi S, et al. 2007. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 26:407–419.
91. Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ. 1986a. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 68:46–57.
92. Metcalf D, Burgess AW, Johnson GR, Nicola NA, Nice EC, DeLamarter J, Thatcher DR, Mermod JJ. 1986b. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF. J Cell Physiol 128:421–431.
93. Metcalf D, Di Rago L, Mifsud S. 2002. Synergistic and inhibitory interactions in the in vitro control of murine megakaryocyte colony formation. Stem Cells 20:552–560.
94. Metcalf D, Nicola NA, Gearing DP. 1990. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76:50–56.
95. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, et al. 2016. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 127:325–332.
96. Möhle R, Green D, Moore MA, Nachman RL, Rafii S. 1997. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94:663–668.
97. Müller-Newen G, Stope MB, Kraus T, Ziegler P. 2017. Development of platelets during steady state and inflammation. J Leukoc Biol 101:1109–1117.
98. Nagler A, Deutsch VR, Varadi G, Pick M, Eldor A, Slavin S. 1995. Recombinant human interleukin-6 accelerates in-vitro megakaryocytopoiesis and platelet recovery post autologous peripheral blood stem cell transplantation. Leuk Lymphoma 19:343–349.
99. Nandurkar HH, Robb L, Tarlinton D, Barnett L, Köntgen F, Begley CG. 1997. Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 90:2148–2159.
100. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, et al. 2000. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 6:25–34.
101. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R, Goldman SJ. 1993. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 81:901–908.
102. Ng AP, Kauppi M, Metcalf D, Di Rago L, Hyland CD, Alexander WS. 2012. Characterization of thrombopoietin (TPO)-responsive progenitor cells in adult mouse bone marrow with in vivo megakaryocyte and erythroid potential. Proceedings of the National Academy of Sciences 109:2364–2369.
103. Ng AP, Kauppi M, Metcalf D, Hyland CD, Josefsson EC, Lebois M, Zhang J-G, et al. 2014. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proceedings of the National Academy of Sciences 111:5884–5889.
104. Nimmo RA, May GE, Enver T. 2015. Primed and ready: understanding lineage commitment through single cell analysis. Trends Cell Biol 25:459–467.
105. Nishimura S, Nagasaki M, Kunishima S, Sawaguchi A, Sakata A, Sakaguchi H, Ohmori T, et al. 2015. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol 209:453–466.
106. Niswander LM, Fegan KH, Kingsley PD, McGrath KE, Palis J. 2014. SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury. Blood 124:277–286.
107. Notta F, Zandi S, Takayama N, Dobson S, Gan OI, Wilson G, Kaufmann KB, et al. 2016. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science 351:aab2116.
108. Paul F, Arkin Y, Giladi A, Jaitin DA, Kenigsberg E, Keren-Shaul H, Winter D, et al. 2015. Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors. Cell 163:1663–1677.
109. Pecci A, Ragab I, Bozzi V, De Rocco D, Barozzi S, Giangregorio T, Ali H, et al. 2018. Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim. EMBO Mol Med 10:63–75.
110. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, et al. 2006. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270.
111. Pitchford SC, Lodie T, Rankin SM. 2012. VEGFR1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. Blood 120:2787–2795.
112. Potts KS, Sargeant TJ, Dawson CA, Josefsson EC, Hilton DJ, Alexander WS, Taoudi S. 2015. Mouse prenatal platelet-forming lineages share a core transcriptional program but divergent dependence on MPL. Blood 126:807–816.
113. Pronk CJH, Rossi DJ, Månsson R, Attema JL, Norddahl GL, Chan CKF, Sigvardsson M, et al. 2007. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell 1:428–442.
114. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Månsson R, Thorén LA, et al. 2007. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 1:671–684.
115. Salim JP, Glembotsky AC, Lev PR, Marin Oyarzún CP, Goette NP, Molinas FC, Marta RF, Heller PG. 2017. Differential expression of SDF-1 receptor CXCR4 in molecularly defined forms of inherited thrombocytopenias. Platelets 28:602–606.
116. Sangkhae V, Etheridge SL, Kaushansky K, Hitchcock IS. 2014. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood 124:3956–3963.
117. Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, Moore S, et al. 2013. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 502:232–236.
118. Saur SJ, Sangkhae V, Geddis AE, Kaushansky K, Hitchcock IS. 2010. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 115:1254–1263.
119. Schumacher A, Denecke B, Braunschweig T, Stahlschmidt J, Ziegler S, Brandenburg L-O, Stope MB, et al. 2015. Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy. J Hematol Oncol 8:64.
120. Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, et al. 2002. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 30:1044–1050.
121. Scott CL, Robb L, Mansfield R, Alexander WS, Begley CG. 2000. Granulocyte-macrophage colony-stimulating factor is not responsible for residual thrombopoiesis in mpl null mice. Exp Hematol 28:1001–1007.
122. Seita J, Ema H, Ooehara J, Yamazaki S, Tadokoro Y, Yamasaki A, Eto K, et al. 2007. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci USA 104:2349–2354.
123. Seo A, Ben-Harosh M, Sirin M, Stein J, Dgany O, Kaplelushnik J, Hoenig M, et al. 2017. Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin. Blood 130:875–880.
124. Sigurjónsson OE, Gudmundsson KO, Haraldsdóttir V, Rafnar T, Agnarsson BA, Gudmundsson S. 2004. Flt3/Flk-2 ligand in combination with thrombopoietin decreases apoptosis in megakaryocyte development. Stem Cells Dev 13:183–191.
125. Sigurjónsson OE, Gudmundsson KO, Haraldsdóttir V, Rafnar T, Gudmundsson S, Guomundsson KO, Guomundsson S. 2002. Flt3/Flk-2-ligand in synergy with thrombopoietin delays megakaryocyte development and increases the numbers of megakaryocyte progenitor cells in serum-free cultures initiated with CD34+ cells. J Hematother Stem Cell Res 11:389–400.
126. Sparger KA, Ramsey H, Lorenz V, Liu Z-J, Feldman HA, Li N, Laforest T, Sola-Visner MC. 2018. Developmental differences between newborn and adult mice in response to romiplostim. Platelets 29:365–372.
127. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, et al. 1994. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91:5592–5596.
128. Stasi R, Bosworth J, Rhodes E, Shannon MS, Willis F, Gordon-Smith EC. 2010. Thrombopoietic agents. Blood Rev 24:179–190.
129. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, et al. 2012. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610–618.
130. Teofili L, Larocca LM. 2011. Advances in understanding the pathogenesis of familial thrombocythaemia. Br J Haematol 152:701–712.
131. Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AY, Moore JO, et al. 1996. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607–3614.
132. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H. 1992. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327–331.
133. Terrault NA, Hassanein T, Howell CD, Joshi S, Lake J, Sher L, Vargas H, et al. 2014. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol 61:1253–1259.
134. Thiele W, Krishnan J, Rothley M, Weih D, Plaumann D, Kuch V, Quagliata L, et al. 2012. VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis. Blood 120:1899–1907.
135. Tiedt R, Coers J, Ziegler S, Wiestner A, Hao-Shen H, Bornmann C, Schenkel J, et al. 2009. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 113:1768–1777.
136. Tijssen MR, Ghevaert C. 2013. Transcription factors in late megakaryopoiesis and related platelet disorders. J Thromb Haemost 11:593–604.
137. Tomer A, Harker LA. 1996. Measurements of in vivo megakaryocytopoiesis: studies in nonhuman primates and patients. Stem Cells 14 Suppl 1:18–30.
138. Tong W, Lodish HF. 2004. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J. Exp. Med 200:569–580.
139. Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, et al. 2017. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med 376:1540–1550.
140. Vilaine M, Gourain V, Cleyrat C, Feron D, Girodon F, Morineau N, Harutyunyan A, et al. 2012. Germline MPLW515R Mutation in a Family with Isolated Thrombocytosis. ASH Annual Meeting Abstracts 120:1764.
141. Walne AJ, Dokal A, Plagnol V, Beswick R, Kirwan M, la Fuente de J, Vulliamy T, Dokal I. 2012. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. Haematologica 97:524–528.
142. Wang B, Nichol JL, Sullivan JT. 2004. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76:628–638.
143. Wang H, Zheng X, Behm FG, Ratnam M. 2000. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood 96:3529–3536.
144. Wang JF, Liu ZY, Groopman JE. 1998. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 92:756–764.
145. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. 1998. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 18:49–52.
146. Xiao M, Wang Y, Tao C, Wang Z, Yang J, Chen Z, Zou Z, et al. 2017. Osteoblasts support megakaryopoiesis through production of interleukin-9. Blood 129:3196–3209.
147. Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL, Ema H, Nakauchi H. 2013. Clonal Analysis Unveils Self-Renewing Lineage-Restricted Progenitors Generated Directly from Hematopoietic Stem Cells. Cell 154:1112–1126.
148. Yatomi Y, Ruan F, Hakomori S, Igarashi Y. 1995a. Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood 86:193–202.
149. Yatomi Y, Ruan F, Ohta J, Welch RJ, Hakomori S, Igarashi Y. 1995b. Quantitative measurement of sphingosine 1-phosphate in biological samples by acylation with radioactive acetic anhydride. Anal Biochem 230:315–320.
150. Yeaman MR. 2014. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol 12:426–437.
151. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, et al. 1996. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93:407–411.
152. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, Gomei Y, et al. 2007. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 1:685–697.
153. Zhang L, Orban M, Lorenz M, Barocke V, Braun D, Urtz N, Schulz C, et al. 2012. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med 209:2165–2181.